Drug Trial Radar · NCT05117710
IMPase in Treatment-resistant Depression
Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 22, 2021
Primary completion
May 31, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council; Sound Pharmaceuticals, Incorporated
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This experimental medicine study will examine the effects of a brief period (seven days) of 'add on' ebselen (SPI-105) treatment in patients with resistant depression to see if ebselen produces changes in emotional responses consistent with a potential clinical antidepressant effect. The investigators will also seek to confirm ebselen's mode of action on IMPase by measuring changes in a brain chemical called inositol, using a magnetic imaging method. Half of the participants will receive ebselen and the other half placebo.
Conditions
- Depressive Disorder, Treatment-Resistant
Interventions
EbselenDrug
Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
PlaceboDrug
Matched placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in positive and negative facial expression recognition taskTime frame: Change between groups from baseline to day 7
- Change in misclassifications on emotional processing taskTime frame: Change between groups from baseline to day 7
- Change in reaction time on emotional processing taskTime frame: Change between groups from baseline to day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurosciences Building, Dept. Psychiatry, Warneford Hospital
Oxford, Oxfordshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.